Cargando…
Mineralocorticoid receptor antagonists use in patients with heart failure and impaired renal function
AIMS: Impaired renal function is a major contributor to the low proportion of mineralocorticoid receptor antagonist (MRA) treatment in patients with heart failure with reduced ejection fraction (HFrEF). Our aims were to investigate the impact of MRA treatment on all-cause mortality and worsening ren...
Autores principales: | Jonsson Holmdahl, Anna, Norberg, Helena, Valham, Fredrik, Bergdahl, Ellinor, Lindmark, Krister |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553049/ https://www.ncbi.nlm.nih.gov/pubmed/34710128 http://dx.doi.org/10.1371/journal.pone.0258949 |
Ejemplares similares
-
Obstacles to mineralocorticoid receptor antagonists in a community‐based heart failure population
por: Jonsson, Anna, et al.
Publicado: (2018) -
Motives, frequency, predictors and outcomes of MRA discontinuation in a real-world heart failure population
por: Jonsson Holmdahl, Anna, et al.
Publicado: (2022) -
Comparison of creatinine‐based methods for estimating glomerular filtration rate in patients with heart failure
por: Jonsson, Anna, et al.
Publicado: (2020) -
Eligibility of sacubitril–valsartan in a real‐world heart failure population: a community‐based single‐centre study
por: Norberg, Helena, et al.
Publicado: (2018) -
Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors
por: Norberg, Helena, et al.
Publicado: (2019)